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1. Introduction  
The principal routes of cocaine administration are oral, intranasal, intravenous, and 
inhalation. The slang terms for these routes are, respectively, "chewing," "snorting," 
"mainlining," "injecting," and "smoking" (including freebase and crack cocaine). Cocaine use 
ranges from occasional use to repeated or compulsive use, with a variety of patterns 
between these extremes. There is no safe way to use cocaine. Any route of administration 
can lead to absorption of toxic amounts of cocaine, allowing to acute cardiovascular or 
cerebrovascular emergencies that could result in sudden death. Repeated cocaine use by any 
route of administration can produce addiction and other adverse health consequences. 
Those who snort or sniff cocaine through their noses suffer damage to their nasal and sinus 
passages. These include nasal crusting, nosebleeds, nasal congestion, irritation, facial pain 
caused by sinusitis and hoarseness. 
Cocaine addiction changes the responsiveness of the brain to various neurotransmitters or 
chemicals. The development of drug addiction involves persistent cellular and molecular 
changes in the Central Nervious System. The brain dopamine, GABA and glutamate 
systems play key roles in mediating drug-induced neuroadaptation. We show some 
physiological changes that can occur in some key pathways in which glutamate, dopamine 
and GABA receptors are involved. These chemical changes cause different effects in users, 
including: anxiety, confusion, dizziness, psychosis, headaches and nausea.  
Cocaine use and addiction affects the sympathetic nervous system (which controls 
automatic functions such as breathing, heartbeat, etc.). This system secretes adrenaline 
which raises ones heart rate, narrows blood vessels and significantly increases blood 
pressure. Chest pain, heart attacks and strokes are common side effects of cocaine use.  
The most widely studied neurobiological characteristic of cocaine addiction is the role 
played by dopamine transmission. It is clear that enhanced dopamine transmission in 
neurons projecting from the ventral mesencephalon to the limbic forebrain, including the 
medial prefrontal cortex (mPFC) and nucleus accumbens (NAc), is the pharmacological 
target for cocaine-induced reinforcement and locomotor stimulation (O’Brien., 2001) 
However, persistence of the behavioral characteristics of cocaine addiction, such as paranoia 
(sensitization) and the propensity to relapse years after the acute rewarding effects of the 
drug have disappeared, indicates that there must also be neuronal substrates undergoing 
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long-term neuroplastic changes. Although studies have endeavored to identify enduring 
changes in dopamine transmission that might underlie behavioral sensitization and the 
reinstatement of drug-seeking (relapse), the results have not been entirely consistent with an 
obligatory role for dopamine. 
Addiction can be viewed as a form of drug-induced neural plasticity. One of the best-
established molecular mechanisms of addiction is up-regulation of the cAMP second 
messenger pathway, which occurs in many neuronal cell types in response to chronic 
administration of opiates or other drugs of abuse. This up-regulation and the resulting 
activation of the transcription factor CREB appear to mediate aspects of tolerance and 
dependence. In contrast, induction of another transcription factor, termed 1FosB, exerts the 
opposite effect and may contribute to sensitized responses to drug exposure. Knowledge of 
these mechanisms could lead to more effective treatments for addictive disorders. 
2. The neurobiology of cocaine addiction 
Dopamine acts as a modulator for many nerve cells throughout the brain. Dopamine is 
responsible for keeping those cells operating at the appropriate levels of activity to accomplish 
our needs and aims (Nestler., 2005). Whenever we need to mobilize our muscles or mind to 
work harder or faster, dopamine drives some of the involved brain cells to step up to the 
challenge (Nestler., 2005).  The targets in brain and other organs are shown in figure 1. 
 
Fig. 1. Cocaine and receptors associated with its toxicity. Continuous lines show the main 
target organs affected; dashed lines represent the secondary neurotransmitters associated. 
(Adapted from Nestler., 2005) 
Dopamine is originated in dopaminergic neurons and launch them into their surroundings. 
Some of the free-floating dopamine molecules latch onto receptor proteins on neighboring 
cells. Once attached, dopamine stimulates the receptors to alter electrical impulses in the 
receiving cells and thereby alter the cells’ function.  To keep the receiving cells in each brain 
region functioning at appropriate intensities for current demands the dopaminergic cells 
continually increase and decrease the number of dopamine molecules they launch. They 
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further regulate the amount of dopamine available to stimulate the receptors by pulling 
some previously released dopamine molecules back into themselves (Nestler., 2005). 
One of the most addictive drugs is cocaine. Cocaine can act mainly on the mesoaccumbens 
dopamine (DA) pathway of the midbrain, extending from the ventral tegumental area 
(VTA) to the nucleus accumbens (NAc).  This pathway is also known as the reward pathway 
as it is the area of the brain that is activated when someone has a pleasurable experience 
such as eating, sex, or receiving praise. Cocaine interferes with the dopamine control 
mechanism: It ties up the dopamine transporter. As a result, with cocaine on board, 
dopamine molecules that otherwise would be picked up remain in action. Dopamine builds 
up and overactivates the receiving cells. However, DA is not the only system affected by 
cocaine. Glutamate and neurotransmission mediated for this aminoacid is also modified and 
has an importantt role in the  mechanism  of this drug addiction. 
 
Fig. 2. The potential mechanisms regulating glutamatergic transmission in the NAc that are 
involved in the reinstatement of drug-seeking behavior. The cocaine-induced changes in 
extrasynaptic glutamate release outlined below are postulated to increase the signal-to-noise 
ratio of synaptically released glutamate, thereby facilitating drug-seeking. 1. Homer protein 
is reduced in the nucleus accumbens, causing a reduction in signaling via mGluR1 receptors 
through inositol trisphosphate (IP3) receptor regulation of internal calcium (Ca) stores. 2. 
Because glutamate release stimulated by mGluR1 receptors results from activation of the 
cystine/glutamate exchanger, it is proposed that down regulated mGluR1 signaling may 
mediate the reduced activity of the cystine/glutamate exchanger produced by chronic 
cocaine administration. 3. The reduced heteroexchange of extracellular cystine (C) for 
intracellular glutamate (E) in glia results in reduced basal extracellular glutamate and 
reduced tone on mGluR2/3 presynaptic autoreceptors. 4. This reduced tone, accompanied 
by mGluR2/3 residing in a more phosphorylated (desensitized) state, results in reduced 
inhibitory regulation of synaptically released glutamate (Glu) (Adapted from Kalivas., 2004) 
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The way in which this sequence of adaptations could synergize to dysregulate presynaptic 
glutamate transmission in cocaine addiction is illustrated in Figure 2. This hypothetical 
model describes how reduced Homer1bc could account for reduced activity of the cystine-
glutamate exchanger and the accompanying reduced basal levels of extracellular glutamate. 
The reduced levels of glutamate, combined with desensitization of the mGluR2/3 receptor, 
results in a loss of regulatory feedback on synaptic glutamate release. Thus, lower basal 
levels of glutamate, combined with increased release of synaptic glutamate in response to 
activation of prefrontal cortical afferents to the NAc, results in an amplified signal and 
behavioral drive to engage drug seeking (e.g. to relapse). In addition to adaptations in 
presynaptic and possibly glial release of glutamate that regulate the expression of 
sensitization and/or reinstatement  a variety of changes in postsynaptic glutamate 
transmission have been documented in the NAc. Interestingly, although presynaptic release 
of glutamate was augmented by withdrawal from repeated cocaine, most data indicate a 
reduction in postsynaptic responses to glutamate (Kalivas., 2004). 
3. Brain changes during cocaine addiction 
Animal studies of cocaine´s action have focused on a set of subcortical gray matter of some 
structures as paralimbic cortices, that are involved in the mediation of reward and 
reinforcement, most notably the ventral tegmental area of the midbrain, the nucleus 
accumbens, the amygdala, and regions of the prefrontal cortex (Makris et al., 2004). Existing 
studies of brain structure in cocaine users have reported abnormalities only in brain regions 
connected to the amygdala, such as the orbitofrontal and anterior cingulate cortex (Franklin 
et al., 2002; Matochik et al., 2003). Markis et al., (2004) sought to evaluate the hypothesis that 
topological and volumetric abnormalities may exist in the amygdala of cocaine-dependent 
subjects that may represent a predisposition to cocaine addiction, or an adaptation to 
protracted exposure to the drug. Amygdala volume and topology were assessed by 
segmentation-based morphometric analysis, and absolute quantitative volumetric measures 
were performed. It was observed that amygdala volume of cocaine-dependent subjects was 
significantly smaller than the one of matched controls. 
The amygdala volumes of cocaine-dependent subjects were similar for each hemisphere, 
whereas those of their matched controls had clear laterality differences. In addition, 
amygdala volume in addicts did not correlate with (1) measures of anxiety or depression, (2) 
any measure of the amount of cocaine use, or (3) age at which cocaine use began (Makris et 
al., 2004) 
Barrós-Loscertales et al., (2011) reported reduced gray matter (GM) volume in the striatum 
and in the supramarginal gyrus. Likewise, another set of cortical and subcortical structures, 
such as the amygdala, the insula and dorsolateral prefrontal cortex, were seen to have 
volume reductions related to years of cocaine exposure (Barrós-Loscertales et al., 2011). All 
these structural changes associated with cocaine addiction seem to merge in the striato-
cortico-limbic circuitry linked not only to addiction, but also to the wider set of disinhibitory 
disorders (Barrós-Loscertales et al., 2011). Although causal relationships are very difficult to 
determine in human studies, the significant relationship between years of use and reduced 
GM volumes are consistent with these volumetric effects arising from the cumulative 
exposure to cocaine or the concomitant lifestyle (e.g., stress) that accompanies prolonged 
drug use (Yücel et al., 2008). 
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In other aspects, Ersche et al., (2011) found some differences between healthy and cocaine 
users, specially in the gray matter abundance in some regions of the brain. There was 
widespread significant loss of grey matter in orbitofrontal cortex bilaterally in the cocaine 
user group. Grey matter volume was also abnormally reduced in the insula, the medial 
frontal and anterior cingulate cortex, temporoparietal cortex and the cerebellum. In contrast 
to this extensive system of decreased cortical grey matter volume, cocaine users also showed 
a significant increase of grey matter volume mainly localized to basal ganglia structures 
(including putamen, caudate nucleus and pallidum), and cerebellum (figure 3).  
 
Fig. 3. Whole-brain maps of significant differences in grey matter volume between healthy 
volunteers and cocaine users. Voxels coloured blue indicate brain areas in which cocaine 
users have reduced grey matter volume compared with healthy volunteers, and voxels 
coloured red indicate brain areas in which cocaine users have abnormally increased grey 
matter volume. These results were generated by permutation testing of voxel cluster 
statistics with cluster-wise P50.001, at which level we expect less than one false positive 
cluster per map. The statistical results are overlaid on the FSL MNI152 standard T1 image 
and the numbers beneath each section of the image refer to its position (mm) relative to the 
intercommissural plane in standard stereotactic space. L = left; R = right. (Ersche et al., 2011) 
In addition, it has been found that the caudate enlargement in cocaine users was associated 
with significant attentional impairments, whereas the reduction in grey matter in the 
orbitofrontal cortex was associated with cocaine-related compulsivity. The abnormal 
changes in grey matter in the striatum and in the orbitofrontal cortex were both related to 
the duration of cocaine abuse (Ersche et al., 2011). 
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In another interesting description, Ersche et al., (2011) showed some maps of brain regions 
demonstrating significant association between grey matter volume and measures of 
duration of cocaine use, compulsivity and impulsivity in the group of cocaine users (figure 
4). This study allow see that is possible find some positive and negative correlations 
between grey matter and duration of cocaine use, or compulsive cocaine taking or 
impulsivity in cocaine users.  
 
Fig. 4. Maps of brain regions. Regions where grey matter volume correlated significantly 
with the duration of cocaine use in drug users are indicated in orange. Regions that 
correlated significantly with compulsive cocaine-taking are coloured in green. Regions 
where grey matter volume correlated significantly with the inattention component of 
impulsivity in cocaine users are indicated in red (if the correlation was positive) and blue (if 
the correlation was negative). The scatter plots beneath each section of the brain image show 
the correlation between these measures and the total grey matter volume for each drug user. 
The numbers above each section of the image refer to its plane position (mm) relative to the 
origin in MNI stereotactic space. L = left; R = right (Ersche et al., 2011). 
In addition, there are differences between the cocaine-dependent and healthy groups. For 
example, the cocaine users had higher depressive scores than the healthy people, and fewer 
years in formal education (11.5 compared to 12.3 years). Most of the cocaine users also had 
nicotine dependence (83%), some also had alcohol dependence (27%), cannabis dependence 
(18%) and heroin dependence (7%). These factors may also have been related to the brain 
differences seen, rather than just the cocaine use. Morever, Ersche et al., (2011), noted that 
impulsivity is a complex trait and that the measures they used would not have captured all 
aspects of it.  
4. The signaling pathways involved in cocaine addiction 
The drugs of abuse differ greatly in their chemical structure, they act on their own unique 
target that are mostly proteins involved in synaptic transmission, although different drugs 
affect different neurotransmitter systems (Nestler, E., 2004). 
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All addictive drugs facilitate dopamine transmission. The dopamine projection to the 
prefrontal cortex (PFC), nucleus accumbens (NAc) and amygdala is a primary site of 
pharmacological action by cocaine, as well as a site where addictive behaviors such as 
relapse and sensitization can be initiated (Berridge and Robinson., 1998). The regions of the 
prefrontal cortex most clearly tied to addiction in both neuroimaging studies in addicts and 
lesion/pharmacological studies in animal models of addiction (rats) are the anterior 
cingulate/prelimbic cortex and the ventral orbital cortex (Neisewander et al., 2000; 
Goldstein and Volkow., 2002; Kalivas., 2004). 
The NAc is composed of two compartments termed the core and the shell (Zahm and Brog., 
1992) and, although the shell is more clearly associated with dopamine-dependent reward, 
the core has been linked to the enduring cellular changes elicited by repeated use of 
addictive drugs (Di Ciano and Everitt., 2001; Kalivas and McFarland., 2003). The projections 
from the amygdala and prefrontal cortex to the nucleus accumbens are glutamatergic, as are 
the reciprocal connections between the basolateral amygdala and prefrontal cortex (figure 
5). The prefrontal cortex also sends glutamatergic efferents to the dopamine cell body region 
in the ventral tegmental area (VTA). This circuit has primary output through co-localized γ-
amino butyric acid (GABA)ergic and peptidergic neurons in the NAc that project to the 
ventral pallidum (PV) and ventral tegmental area (Kalivas., 2004). 
The changes in the NAc, influenced by activation of dopamine receptors, are critically 
involved in behavioral adaptations (Marinelli and White., 2000). Natural rewards, but also 
drugs of abuse, increase VTA release of dopamine in downstream structures such as the 
NAc (Di Chiara, 2002; Schultz., 2002). However, an essential difference between natural 
rewards and drugs of abuse is that, over time, the dopamine response to the natural 
rewards, but not drugs of abuse, diminishes (Kalivas and O'Brien., 2008). Additionally, the 
amount of dopamine released following administration of a drug of abuse, particularly 
cocaine, typically exceeds what occurs following exposure to a natural reward. Thus, the 
repeated large release of dopamine is believed to be critical in the development of addiction, 
as it alters and modifies structures and their connections (Uys and LaLumiere,. 2008). 
 
Fig. 5. The schematic diagram identify the critical structures involved in drug reward and 
relapse to cocaine seeking.  VTA, Ventral tegmental area; PFC, Prefrontal cortex; NAc, 
Nucleus accumbens; VP, Ventral pallidum. 
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The VTA–NAc, so called mesolimbic, pathway seems to be a site where virtually all drugs of 
abuse converge to produce their acute reward signals. Two major mechanisms are involved: 
first, all drugs of abuse increase dopamine-mediated transmission in the NAc, although by 
very different mechanisms; second, some drugs also act directly on NAc neurons by 
dopamine-independent mechanisms (Everitt and Wolf., 2002).  
An interesting point is the intracellular event precipitated by stimulation of dopamine 
receptors as a result of repeated use of cocaine. In dopamine D1 receptor stimulation of 
cAMP-dependent protein kinase (or PKA) and subsequent changes in protein function and 
gene expression in the NAc and VTA appear critical to establishing sensitization (Nestler., 
2001). The most well-characterized effect of increased cAMP-dependent protein kinase 
activity is the induction of cAMP response element and the subsequent change in ∆FosB and 
cyclin-dependent kinase 5 (Nestler et al., 2001; Lu et al., 2003). In addition to the immediate 
consequences of dopamine receptor signaling, calcium/calmodulin and ras/mitogen-
activated protein kinase activity in the ventral tegmental area are critical for the 
development of sensitization (figure 6).  The dopamine D1 receptor stimulation–dependent 
activation of L-type Ca2+ channels and CaMKII facilitates the reinstatement of cocaine 
seeking by promoting the transport of GluA1-containing AMPA receptors in the NAc shell 
to the plasma membrane. The CaMKII activity in the NAc shell may be an essential link 
between dopamine and glutamate systems involved in the neuronal plasticity underlying 
cocaine craving and relapse (figure 6). (Wolf et al., 2004; Boehm and Malinow., 2005; 
Schmidt and Pierce., 2010). 
 
Fig. 6. Pathway between NAc shell dopamine and glutamate systems, via L-type Ca2+ 
channels and Ca2+/calmodulin kinase II (CaMKII), which is proposed to underlie the 
reinstatement of cocaine seeking. (Adapted from Schmidt and Pierce., 2010).  
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In contrast to dopamine, glutamate transmission appears to be a primary contributor in the 
majority of examples of enduring neuroplasticity in the brain, and the development and 
expression of cocaine addiction is no exception (Winder et al., 2002).  The activation of 
glutamatergic efferents from the amygdala and prefrontal cortex is critical in the expression 
of addictive behaviors. 
Cocaine indirectly influences glutamate transmission in the limbic system, including the 
NAc, producing persistent changes in neuronal function that can alter the behavioral effects 
that generate this drug. (Gass and Olive., 2008; Uys and LaLumiere., 2008; Thomas et al., 
2008). Thus, maladaptive forms of neuroplasticity in the NAc contribute to cocaine-seeking 
behavior, and reversing these cocaine-induced neuroadaptations in glutamatergic 
transmission may prevent relapse of cocaine taking. 
The interaction between glutamate and dopamine in VTA and NAc is rather complex, but in 
simplified terms, glutamatergic input to the VTA increases the activity of dopaminergic cells 
and enhances dopamine release in the NAc (Tzschentke., 2001). At the level of the NAc, 
glutamate also facilitates dopaminergic transmission, presumably by presynaptically 
influencing dopamine release (Floresco et al., 1998; Tzschentke and Schmidt., 2003). 
5. The role of glutamate, and GABA receptors in cocaine addiction 
The glutamate as neurotransmitter interacts with specific ionotropic glutamate receptors 
(iGluR) or metabotropic glutamate receptors (mGluR) (Dingledine et al., 1999; Cull-Candy et 
al., 2001). The ionotropic family of glutamate receptors consists of three subfamilies of 
tetrameric receptors; N-methyl-D-aspartate (NMDA) receptors, α-amino-3-hydroxy-5-
methylisoxazole-4-propionic acid receptors (AMPAR), and kainate receptors. Agonist 
binding induces a conformation change in NMDA, AMPA, and kainate receptors that 
increases the probability of channel opening. Different subunit compositions of ionotropic 
glutamate receptors produce functionally diverse NMDA, AMPA, and kainate receptors 
that are expressed differently throughout the brain (Dingledine et al., 1999). 
The latter are the G protein-coupled receptor. Through various G proteins, they connect to 
multiple second messenger systems. There are three functional groups of mGluRs (group I–
III) classified from eight subtypes (mGluR1–8) (Conn and Pin., 1997). Group I mGluRs 
(mGluR1/5 subtypes) are positively coupled to phospholipase Cβ1 through Gαq proteins. 
Activation of mGluR1/5 increases phosphoinositol hydrolysis, resulting in intracellular Ca2+ 
release and protein kinase C (PKC) activation (Conn and Pin, 1997). Both group II 
(mGluR2/3) and group III (mGluR4/6/7/8) receptors are negatively coupled to adenylyl 
cyclase through Gαi/o proteins. Their activation reduces cAMP formation and inhibits 
protein kinase A (PKA).  
Group I mGlu receptors can also couple Homer proteins through a Homer-phosphatidyl-
inositol 3-kinase enhancer (PIKE) adaptor complex (Szumlinski et al., 2008). This is 
particularly important for mGlu receptor trafficking into and out of the synapse and also to 
functionally connect mGlu to iGlu receptors.  
5.1 Ionotropic receptors and cocaine 
The glutamate neurotransmission in the NAc core is necessary for cocaine-induced 
behaviors, which are regulated by AMPA receptors (Pierce et al., 1996). In addition, chronic 
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cocaine treatment changes iGluR’s in both the PFC and NAc. In cocaine sensitized rats, there 
is an increase in GluN2B receptors in the NAc shell and decreased Tyr1472 phosphorylation 
in the NAc core with an increase in GluA1 Ser845 phosphorylation in the PFC, NAc shell 
and core (Zhang et al., 2007). Interestingly, glutamate receptor trafficking may be highly 
relevant for cocaine-induced neuroplasticity (Lau and Zukin., 2007). 
Dopamine D1 receptor stimulation of rat PFC cortical neurons increases surface expression 
of GluA1-containing AMPA receptors through a protein kinase A-dependent mechanism 
(Sun et al., 2005). Cocaine self-administration increases synaptic GluA2-lacking AMPA 
receptors in the NAc after withdrawal (Conrad et al., 2008). Likewise when sensitized 
animals are re-exposed to cocaine after 10–14 days of withdrawal, both AMPAR surface 
expression and AMPA/NMDA ratio were shown to be decreased 24 h later (Boudreau et al., 
2007; Ferrario et al., 2010; Kourrich et al., 2007; Thomas et al., 2001). GluA2-lacking AMPA 
receptors may therefore be a novel target for treating cocaine addiction. 
The effect of repeated cocaine exposure on the cellular distribution of AMPARs is of 
functional significance because it has been shown that drug seeking requires AMPAR 
transmission in the NAc (Cornish and Kalivas, 2000; Di Ciano and Everitt, 2001) and that 
enhanced AMPAR transmission in the NAc is associated with enhanced drug seeking 
(Anderson et al., 2008; Conrad et al., 2008; Suto et al., 2004; Wolf and Ferrario, 2010). 
Carrie et al., (2011) showed effects of a single cocaine exposure in rats and the difference 
from those previously reported after repeated cocaine administration. They further 
suggested that cocaine exerts these effects by influencing neuronal circuits rather than 
simply stimulating NAc DA transmission. 
Cocaine injection administered to rats pretreated with repeated cocaine injections results in 
increased glutamate release in the NAc core (McFarland et al., 2003; Pierce et al., 1996; 
Hotsenpiller et al., 2001). There are different neuroadaptations in the accumbens core and 
the accumbens shell. When cocaine is injected during withdrawal from repeated cocaine 
exposure, occurs that cocaine decreased presynaptic glutamate immunoreactivity in the 
accumbens core, but not the accumbens shell (Kozell et al., 2003, 2004). Similarly, cocaine–
induced reinstatement of drug seeking was associated with increased glutamate release in 
the core of the nucleus accumbens, an effect that is attenuated by pharmacological 
inactivation of the medial prefrontal cortex (mPFC) (McFarland et al., 2003). Then, the 
administration of an AMPA receptor antagonist into the NAc blocked the reinstatement of 
cocaine seeking induced by administration of cocaine directly into the mPFC (Park et al., 
2002). The activation of the glutamatergic projection  from the mPFC to the NAc promotes 
cocaine seeking (Park et al., 2002)., a finding supported by brain imaging studies of human 
cocaine addicts, which demonstrate that cocaine craving is associated with metabolic 
activation of the mPFC (Volkow et al., 2005). These findings also demonstrate that 
stimulation of AMPA glutamate receptors in the NAc  plays a critical role in cocaine seeking 
(Schmidt and Pierce., 2010).  
Has been established an association (correlation) between AMPAR phosphorylation and 
enduring behavioral plasticity (behavioral sensitization and more significantly drug-seeking 
behavior), although a causal link between them remains to be proven experimentally (Mao 
et al., 2011). S845/S831 phosphorylation is likely to be up-regulated to increase surface 
AMPAR expression  thereby enhancing AMPAR transmission related to behavioral 
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plasticity (Boudreau and Wolf, 2005; Conrad et al., 2008). However, self-administration of 
cocaine induced lesser S845 phosphorylation in the striatum as compared to acute cocaine 
injection, establishing a tolerance of S845 phosphorylation in response to chronic cocaine 
(Edwards et al., 2007). This tolerance may reflect a down-regulated GluA1 function in 
accumbens neurons and may contribute to cocaine sensitization and cocaine-seeking 
behavior (Sutton et al., 2003; Bachtell et al., 2008). These imply a phosphorylation-dependent 
mechanism for AMPAR plasticity and drug-seeking (Mao et al., 2011).  
In terms of NMDA receptors there is evidence that links post-translational modifications of 
glutamate receptors to excitatory synaptic plasticity and drug-seeking behavior (Di Ciano, 
Everitt, 2001). Generally, modification processes of striatal glutamate receptors are sensitive 
to addictive drugs such as cocaine.  
Dopamine D2 receptors are involved in the regulation of NMDA receptor phosphorylation 
(Liu et al., 2006). A single dose of cocaine induced a heteroreceptor complex formation 
between D2 receptors and GluN2B-containing NMDA receptor in D2 receptor-bearing 
striatopallidal neurons. The interaction of D2 receptors with GluN2B disrupted the 
association of CaMKII with GluN2B, thereby reducing phosphorylation at the CaMKII-
sensitive site S1303 and inhibiting NMDA receptor currents. Behaviorally, this 
phosphorylation, involving D2–GluN2B interaction, suppressed the inhibitory indirect 
pathway to promote a full motor response to cocaine. Chronic cocaine reduced GluN1 S896 
phosphorylation in the rat frontal cortex at 24 h, although not 14 days after of withdrawal 
(Loftis and Janowsky, 2002). However, acute, repeated, and self-administration of cocaine 
increased GluN1 S897 phosphorylation in the rat striatum (Edwards et al., 2007). Then the 
fact that S897 is a sensitive site modified by cocaine can show the importance of post-
translational modifications in NMDA receptor plasticity and drug craving (Mao et al., 2011; 
Hemby et al., 2005).  
5.2 Metabotropic receptors and cocaine 
An acute injection of cocaine did not alter the total accumbal expression of mGluR5 protein 
but was enough to reduce surface expression of mGluR5 in the nucleus accumbens, 
suggesting that trafficking of mGluRs plays a critical role in cocaine-induced synaptic 
plasticity (Fourgeaud et al., 2004). There is evidence that indicates that mGluR2/3 and 
mGluR5 proteins are redistributed to the synaptosomal membrane fraction after a period of 
extended, but not acute, forced abstinence (Ghasemzadeh et al., 2009).  
In fact, mGluR2/3s have already been demonstrated to play a key role in the excessive 
glutamate release believed to promote drug-seeking (Kalivas, 2004). Acute and chronic 
cocaine treatment alter the normal function, expression or traficking of group I metabotropic 
receptors in the NAc of rats (Mitrano et al., 2008). A single injection of cocaine decreases the 
proportion of plasma membrane-bound mGluR1a in the NAc shell dendrites 45 minutes 
after the injection, while chronic cocaine treatment decreased mGluR1a in the NAc core 
dendrites. This is in contrast to acute and chronic cocaine treatment having no effect on the 
localization of mGluR5 receptors (Mitrano et al., 2008).  Another study found a decrease in 
mGluR1a in the NAc shell of chronic cocaine treated rats (Ary and Szumlinski., 2007; Uys 
and LaLumiere., 2008). Mice lacking mGluR5 receptors do not self-administer cocaine or 
show an increase in locomotor activity after cocaine treatment, despite having a similar 
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increase in dopamine levels in the NAc as compared to wild-type mice (Chiamulera et al., 
2001). Activation of the perisynaptic group II mGluR receptors, mGluR2/3, decreases 
presynaptic glutamate release in the NAc (Xi et al., 2002; Moran et al., 2005) 
Likewise the cocaine-induced plasticity in excitatory synapses within the NAc initiates 
adaptive changes in neuronal ensembles that lead to drug-seeking behavior and alters 
subsequent physiological responses to cocaine, including increased trafficking and surface 
expression of AMPA receptors, during protracted withdrawal (Schmidt and Pierce., 2010). 
Glutamate receptors antagonists produce undesirable side effects on neurological functions. 
Therefore, modulation, rather than blockade, of glutamatergic transmission would be more 
advantageous. Accordingly, glutamate transmission-modulating agents have emerged as 
possible therapeutic compounds in preclinical and clinical studies (Kalivas, 2004). 
5.3 GABA in cocaine addiction 
GABA is an inhibitory neurotransmitter that is found primarily in the brain. As mentioned 
previously, the VTA plays a role in the reinforcing effects of most drugs of abuse, including 
cocaine, and consists of both dopaminergic and GABAergic cell bodies along with afferent 
terminals containing a variety of neurotransmitters. Then GABA acts as the primary 
inhibitory neurotransmitter in the VTA, and the GABAergic environment in the VTA has 
been understudied in the realm of cocaine abuse. High GABA levels result in low levels of 
dopamine. However cocaine diminishes transmission through of type a GABA-A receptor 
on dopaminergic cells in the VTA, and stimulation of other GABA-B receptor, instead, can 
counteract the reinforcing properties of cocaine.  
The activation of GABA-A and GABA-B receptors inhibit VTA neurons, reduce dopamine 
release, and reduce cocaine-induced increases in extracellular dopamine (Klitenick et al., 
1992; Fadda et al., 2003). GABA-A receptors are also located on GABAergic interneurons 
presynaptic to dopaminergic VTA neurons, and activation of these receptors would be 
predicted to inhibit GABAergic interneurons, disinhibit VTA neurons, enhance dopamine 
release, and enhance cocaine-induced increases in extracellular dopamine (Klitenick et al., 
1992; Xi and Stein, 1998). Now, given the interactions between GABA and dopaminergic 
systems, GABAergic ligands may be useful for modifying some of the abuse-related effects 
of cocaine. Then the use of an among mechanistically diverse GABA agonists, high-efficacy 
GABA-A modulators may be the most effective for modifying the abuse-related effects of 
cocaine (Barrett et al., 2005). 
On the other hand, acute cocaine toxicity is frequently associated with seizures. The 
mechanisms underlying the convulsant effect of cocaine are not well understood. 
Previously, studies have shown that cocaine depresses whole-cell current evoked by 
gamma-aminobutyric acid (GABA) in hippocampal neurons freshly isolated from rats. 
Cocaine's effect was voltage-independent and concentration-dependent. Ye and Ren, (2006), 
suggest that cocaine induces an increase from intracellular calcium [Ca]i, which stimulates 
phosphatase activity and thus leads to dephosphorylation of GABA receptors. This 
dephosphorylation-mediated disinhibitory action may play a role in cocaine-induced 
convulsant states. 
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6. Therapeutical targets for cocaine addiction 
Studying the pathways involved in cocaine addiction, it is possible to know that 
pharmaceutical industries are hardly working on pharmacotherapies to treat this addiction 
and that must be directed toward the molecular transductors of abnormalities found in 
cocaine users. In the present section, we´ll show some of the most used pharmacotherapies 
and the usual targets that are regulated for them. In general, we can say that most of those 
therapies have been used firstly in other pathologies and assayed in cocaine addiction 
according to their action mode or target. 
Topiramate: is a sulphamatefructopyranose derivative, thought to antagonize a drug’s 
rewarding effects by inhibiting mesocorticolimbic dopamine release via the gamma 
aminobutyric acid (GABA) activity and inhibition of glutamate function after drug intake. 
Through this activity, topiramate may decrease extracellular release of dopamine in the VTA 
projecting to the nucleus accumbens. This action may mediate drug-seeking behaviors and 
craving by reducing the rewarding effects associated with drug use (Johnson et al., 2004). 
Disulfiram: inhibits plasma and microsomal carboxylesterases and plasma cholinesterase 
that inactivate cocaine systemically thereby increasing blood levels of cocaine without any 
cardiovascular toxicity. Another important role is that disulfiram chelates copper, and since 
copper is essential in the function of the dopamine beta-hydroxylase enzyme, disulfiram 
inhibits the conversion of dopamine to norepinephrine. Dopamine betahydroxylase 
inhibition by disulfiram leads to decreases in peripheral and central norepinephrine and 
increases in dopamine levels. This effect is believed to contribute to disulfiram’s efficacy in 
treating cocaine addiction (McCance-Katz et al., 1998) 
Ondansetron: Post-synaptic 5-HT3 receptors are located densely on the terminals of 
corticomesolimbic dopamine containing neurons, where they promote DA release. A 
primary effect of ondansetron a 5-HT3 antagonist is to decrease dopamine release, especially 
under suprabasal conditions in these regions (Haile et al., 2009) 
Baclofen: is a GABA B receptor agonist used to reduce muscle spasticity in different 
neurological diseases. It is believed to modulate cocaine-induced dopamine release in the 
nucleus accumbens. In animal studies baclofen was found to reduce cocaine self-
administration, reinstatement, and cocaine seeking behaviors in rats suggesting its potential 
utility as a medication for treatment of cocaine addiction. In humans, an open label study 
found that baclofen 20 taken three times daily significantly reduced cocaine craving in 
cocaine-dependent subjects. However, this trial had a sample size of 10 and did not have a 
placebo arm. An analysis of the same data found that baclofen significantly reduced cocaine 
use in the subgroup of patients with the heaviest cocaine use only (Fadda et al., 2003) 
Modafinil: a functional stimulant, is FDA approved for the treatment of narcolepsy and 
idiopathic hypersomnia. The mechanisms underlying modafinil’s therapeutic actions 
remain unknown. It is believed to occupy both the dopamine and norepinephrine 
transporters consistent with a stimulant like effect. In addition, modafinil appears to 
increase release of the excitatory neurotransmitter glutamate, and decrease the inhibitory 
neurotransmitter GABA. Modafinil is usually well tolerated, although up to 3% of patients 
on modafinil experienced cardiovascular side-effects such as hypertension, tachycardia, and 
palpitations. Because of its stimulant-like activity, modafinil was suggested and later tested 
as a treatment for cocaine dependence. It was believed to diminish not only the symptoms 
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of cocaine withdrawal, but also act as a “substitution treatment” for cocaine (Ballon and 
Feifel., 2006). 
Naltrexone: (NTX) has long been available as an orally available antagonist at opioid receptors, 
with a relative selectivity for the μ-opioid receptor at lower doses. It was originally studied as 
a potential treatment for opiate dependence, where it seems to be effective in special cases, but 
not across the broad range of patients. NTX taps into known EtOH actions in a seemingly 
logical manner. EtOH administration leads to release of endogenous opioid peptides, and one 
of the downstream effects of this is to activate mesolimbic dopamine (DA) release. This in turn 
contributes to acute positive reinforcing properties of drugs of abuse (Kreek et al., 2002). 
Consistant with this chain of events, μ-receptor null-mutant mice do not self-administer EtOH 
(Roberts et al., 2000; Heilis and  Egli., 2006). 
Other medications that interact with GABA- or glutamate-mediated neuronal systems have 
been tried as potential treatment for cocaine dependence. While there is preclinical evidence 
that acamprosate can inhibit conditioned place preference to cocaine and attenuates both 
drug and cue-induced reinstatement of cocaine-seeking behavior there is to date, no clinical 
trial testing its utility in treating humans with cocaine dependence. Gabapentin is another 
gabanergic drug used to treat both epilepsy and neuropathic pain. Its exact pharmacological 
mechanism remains unclear. Gabapentin has showed some promising results in an open-
label study and case series suggesting that it might have utility in the treatment of cocaine 
dependence. There are encouraging preclinical data that support the utility of vigabatrin as 
a treatment agent for cocaine dependence. Vigabatrin is another anticonvulsant that 
increases GABA neurotransmission but this time by inhibiting GABA transaminase. It is a 
drug with great potentials but needs to be tested in adequately powered placebo controlled 
randomized studies. Tiagabine is yet another anticonvulsant that increases GABA 
neurotransmission by blocking the presynaptic reuptake of GABA. In 2 randomized clinical 
trials involving cocaine dependent patients who were maintained on methadone, tiagabine 
(12-24 mg/day) was found to decrease cocaine use compared with placebo (Bowers et al., 
2007; Gonzalez et al., 2003) . 
Finally, the use of stimulants has been tried for the treatment of cocaine dependence under 
the premise of a drug substitution for a drug with slower onset formulation and less abuse 
liability. Methylphenidate, a dopamine and nerepinephrine reuptake inhibitor used to treat 
attention deficit hyperactivity disorders (ADHD) was found to be no better than placebo in 
the treatment of cocaine dependent patients without comorbid ADHD. However when used 
in a population with dual diagnosis of cocaine dependence and ADHD, results from clinical 
trials were mixed. While a controlled clinical trial using immediate release methylphenidate 
(90 mg/day) found no difference between the active drug and placebo groups, another trial 
using sustained release methylphenidate (60 mg/day), found significant improvement in 
ADHAD symptoms that were associated with decrease in cocaine use compared with 
placebo. Though medications such as those that facilitate gabaergic function, modulate 
dopaminergic function or act as an agonist replacement therapy show promise in treating 
cocaine dependence, there are certain drawbacks (Levin et al., 2007).  
Other authors (Heilis and Egli., 2006) have organized medication used in cocaine addiction 
in three different groups. The medications described in past paragraphs are classified in the 
“first wave: currently available treatments” and “second wave: the near future”. Those 
medications have been used in mixes between them and have shown interesting results. 
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Table 1 summarizes some aspects related to treatment and targets of first, and second wave 
medications. 
 
Medication 
Group 
(wave) 
Target, mechanism References 
Disulfiram First 
Blocking aldehyde dehydrogenase 
(alcohol treatment), and dopamine 
beta-hydroxylase (cocaine 
dependence) 
Carroll et al., 2004 
Naltrexone 
(NTX) 
First Antagonist at opioid receptors Kirchmayer et al., 2000 
Acamprosate 
(ACM) 
First 
Glutamate antagonist, attenuates 
NMDA signaling through 
spermidine site and actions at 
metabotropic glutamate receptors 
Spanagel & 
Zieglgansberger, 1997; 
Harris et al., 2002. 
NTX and 
ACM mixed 
First 
Opioid receptors, NMDA 
receptors and metabotropic 
receptors 
Rist et al., 2005; Spanagel & 
Mann, 2005. 
Ondansetron Second Serotonin receptors 
Higgins et al., 1992; Meert, 
1993; Tomkins et al., 1995. 
Baclofen Second 
Agonist at GABA-B receptor. 
Treatment when in detected 
additional alcohol dependence 
Stromberg, 2004. 
Topiramate Second 
Proposed effects: blockade of 
voltage dependent sodium 
channels, antagonism of kainite 
receptors and potentiation of 
GABA signaling through 
increased GABA availability 
Zona et al., 1997; Gryder & 
Rogawski, 2003; 
Kaminski et al., 2004, White 
et al.,1997 
Table 1. Medications used in cocaine dependence, showing its classification and possible 
mechanism (or target) of action. The main use of those medications is in alcohol dependence 
treatment but they have shown good results in other dependences as cocaine addiction 
(adapted from Heilis and Egli., 2006) 
The third wave medications in cocaine addiction have been used with promising results. 
The development of pharmacotherapy for cocaine addiction is based on previous strategies 
designed to alleviate other chemical dependencies such as alcoholism and opiate addiction, 
focusing on the neurobiological and the behavioral bases of addiction. To date, however, no 
pharmacotherapy has been approved by the U.S. Food and Drug Administration for cocaine 
dependence, but two major classes of medications have been investigated: (1) dopaminergic 
agents and (2) antidepressants. Studies have been relatively brief for both types of agents 
and have focused on abstinence initiation rather than on relapse prevention. In addition to 
dopaminergic agents and antidepressants, other compounds such as calcium channel 
blockers, have been examined as potential treatments of cocaine dependence (figure 7) 
(Carrera et al., 2004)  
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In the first group, some dopaminergic agents have been used based on the theory that 
chronic cocaine use reduces the efficiency of central DA neurotransmission, several 
dopaminergic compounds, including amantadine, bromocriptine, mazindol, and 
methylphenidate, have been examined as treatments for cocaine abuse. Investigators hoped 
that these dopaminergic agents, which have a fast onset of action, would correct the DA 
dysregulation and alleviate the withdrawal symptoms that often follow cessation of 
stimulant use. 
 
Fig. 7. Classification of medications used for cocaine addiction, based on target and 
mechanism of action (based on Carrera et al., 2004). 
Large array of cocaine analogues and other dopamine uptake inhibitors (see Table 2) 
including analogues of WIN-35,065, GBR-12909, nomifensine, and benztropine have been 
developed in the last years. The largest class of compound studies is the class of 3-
phenyltropane analogues, of which many hundreds have been made and tested. The 
analogues RTI-112 and PTT are in preclinical evaluation. Like cocaine, RTI-112 and PTT both 
have good affinity for all three monoamine transporters, but in contrast to cocaine they enter 
the brain slowly and are long-lasting. A number of other 3-phenyltropanes are potent and 
selective for the dopamine transporter relative to inhibition of serotonin and norepinephrine 
transporters, are long-lasting, and also enter the brain more slowly than cocaine, for 
example, RTI-113 and RTI-177 (Carrera et al., 2004). 
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The effect of inhibiting neurotransmitter uptake is to stimulate neurotransmitter receptors; 
thus the use of direct receptor agonists as substitute agonist medications also has been 
suggested. Data on dopamine receptor agonists have been extensively reviewed. Animal 
studies indicate that dopamine receptor agonists such as apomorphine and bromocriptine 
maintain self-administration in rodents. 
 
Compound CNS target 
RTI-113, RTI-177, GBR-12909 DA uptake inhibitors (selective for DAT) 
Mazindol, methyl phenidate, 
nomifensine, benztropine 
DA uptake inhibitors (not selective) 
Apomorphine, bromocriptine, 
SKF38393, quinpirole 
DA receptor agonists and partial agonist 
Desipramine Antagonist of cocaine binding that spare DA uptake 
Fluoxetine, alaproclate 5HT uptake inhibitors 
Quipazine 5HT receptor agonist 
Ketanserin, ritanserin, 
ondansetron 
Calcium channel blockers 
Table 2. List of some compounds that have been used as pharmacotherapy in cocaine 
addiction and target identified in Central Nervous System (adapted from Carrera et al., 
2004) 
The second class of medications used to treat cocaine dependence, antidepressants, are 
thought to down regulate synaptic catecholamine receptors, and this action is opposite to 
the presynaptic up-regulation caused by chronic stimulant use. Although antidepressants 
have a relatively benign side-effect profile, good patient compliance rates, and lack of abuse 
liability, they have a delayed onset of action ranging from 10 to 20 days. Therefore, the 
physician may consider beginning antidepressant treatment during early withdrawal and 
continuing for weeks or longer as clinically indicated. The tricyclic antidepressant 
desipramine has been studied most extensively as a treatment of cocaine dependence. Early 
studies of desipramine to treat cocaine dependence showed positive results but placebo-
controlled trials have not produced impressive findings. A meta-analysis of placebo-
controlled studies by Levin and Lehman showed that although desipramine did not 
improve retention in treatment, it did produce greater cocaine abstinence relative to placebo. 
However, treatment with desipramine has induced “early tricyclic jitteriness syndrome” 
and cocaine craving, as well as relapse to cocaine use in some patients. Therefore, 
desipramine as pharmacotherapy would hold serious clinical caveats. Additional studies 
have focused on the involvement of the 5HT3 receptor subtype in the neuropharmacology 
of cocaine, but the results obtained are somewhat inconsistent. Several 5HT3-selective 
antagonists, including MDL-72222 and ondansetron were reported to attenuate cocaine-
induced locomotor activityin rodents. However, ondansetron failed to block the reinforcing 
or discriminative-stimulus effects of cocaine in rodents. Several other antidepressants, 
including fluoxetine, sertraline, and trazodone, that work predominantly through 
serotonergic mechanisms also have been used as pharmacotherapy for cocaine dependence. 
Although some reports indicated that treatment with fluoxetine reduced cocaine craving 
and use in cocaine-abusing heroin addicts, other investigators have not found fluoxetine to 
be effective in attenuating cocaine use and withdrawal symptoms. Bupropion, a “second-
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generation” antidepressant, has been studied as pharmacotherapy for cocaine dependence 
(Heilis and Egli., 2006; Carrera et al., 2004) 
Various studies suggest that L-type calcium channel blockers potentially reduce the 
rewarding effects of cocaine. One such compound, the L-type calcium channel blocker 
isradipine (Fig. 7), attenuated the cocaine induced dopamine release in the striatum of rats. 
Another report described isradipine-induced attenuation of condition place preference and 
the discriminative stimulus properties of cocaine. Also, pretreatment with isradipine 
resulted in a dose-dependent decrease in intravenous cocaine self-administration. Because 
of the antihypertensive quality of calcium channel blockers, the potential increase in cardiac 
output in patients with normal ventricular function could complicate their use as 
pharmacotherapies for cocaine abuse (Carrera et al., 2004) 
Notwithstanding the impressive amount of research effort in this area, a large number of 
studies using dopaminergic drugs have failed to yield encouraging results. To date, no 
pharmacotherapeutic agent of this type used on an experimental basis has been shown 
effectiveness that would merit medical implementation. 
7. Perspectives 
The fact that GABA and glutamate are so widely present makes it likely that they will be 
altered during drug addiction. This fact also makes it difficult to treat addiction with drug 
therapy. Say that a drug affects GABA and glutamate in way that relieves craving. Because 
GABA and glutamate are so widely present, these drugs could produce a mess of side 
effects as well. If we had drugs that could selectively stimulate or block certain receptors, 
then we could treat addiction and avoid doing people more harm than good. 
Treatment studies should continue the present emphases on (1) identifying and 
systematically testing pharmacological agents that may be useful in achieving abstinence 
from cocaine and reducing the likelihood of relapse; (2) characterizing and understanding 
the processes and outcomes of existing treatments by using field studies with outcomes 
studied over a 1-year post treatment period and longer; and (3) testing the efficacy of 
specific psychosocial interventions such as psychotherapies, behavioral treatments, and 
relapse prevention strategies. The need for theory-based treatment approaches should be 
recognized. Promising pharmacotherapies also should be field tested in clinical programs to 
understand issues related to compliance with medication regimens. 
Recent efforts to discover new pharmacs have been oriented to get a vaccine for cocaine 
addiction. However, to improve existing treatment, there should be a systematic effort to 
integrate research and treatment. Research should develop and test criteria for client-
treatment matching so that the most cost-effective treatments can be provided for cocaine 
dependent users. Additional research should focus on better understanding motivation as a 
factor for increasing the retention of cocaine users in treatment. This focus would include 
use of motivational incentives to enter and remaining treatment. There is a need to better 
understand the role of self-help in treating cocaine users. 
Additional studies for the current cocaine vaccine are planned to confirm and extend the 
discussed outpatient studies, and there are ongoing developmental studies of alternative 
adjuvants and vaccine constructs which will likely improve the quantity and quality of 
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antibodies produced, as well as the proportion of high response subjects. Such results would 
lead to clinical application of these vaccines for in the treatment of cocaine abusers. Better 
vaccines or newer methods will not be the end of the game for treating substance abuse, 
however. The motivated cocaine addict will need other interventions such as therapy and 
rehabilitation programs in order to overcome this seductive addiction. Anti-drug programs 
in schools should be strengthened, as cocaine addiction often starts before age 20. The 
criminal justice system should reconsider the wholesale incarceration of cocaine users, and 
offer help rather than punishment. Let us hope that in the years ahead anti-cocaine 
vaccination will be one of numerous arrows in our therapeutic quiver to combat drug 
addiction (Kinsey et al., 2010). 
Incorporation of technology into treatment methods is also being explored. Computer-
assisted therapies may offer more consistent and convenient delivery of instruction and 
reinforcement in conjunction with CBT. An additional and innovative approach, to be used 
with a structured treatment program, is the administration of a therapeutic cocaine vaccine. 
The vaccine is shown to inhibit the cocaine ‘high’ through antibodies binding to cocaine in 
the circulation and inhibiting entry to the brain. However, it does not stop drug cravings.  In 
addition, recent findings suggest that only those subjects who attain high (> 43 ug/L) IgG 
anticocaine antibody levels benefited from significantly reduced cocaine use. Unfortunately, 
only 38% of the vaccinated subjects achieved such high IgG levels. Psychosocial therapy is 
still essential in medication and vaccine studies because the underlying issues of the 
dependence and use behavior must be addressed or individuals may relapse or resort to 
misusing another drug. The intent of the vaccine is to immunize motivated patients as part 
of a comprehensive recovery program and to inhibit the reinforcing activity of cocaine and 
decrease the likelihood of relapse (Penberthy et al., 2010). 
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